The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., May. 8, 6:02 AM

Slide #17. Evolus, Inc. Secondary Offering

Company: Evolus, Inc. (NASDAQ:EOLS)
Date announced: 4/21/2021
Shares Offered: 9,000,000
Date of Pricing: 4/21/2021
Price Per Share: $9.50
Secondary Offering Details: Evolus, Inc. (Nasdaq: EOLS) announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. Evolus expects to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares in the offering are to be sold by Evolus. -updated 4/21- Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its public offering of 9,000,000 shares of its common stock at a public offering price of $9.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Evolus are expected to be $85.5 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Evolus has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about April 26, 2021, subject to satisfaction of customary closing conditions. All the shares in the offering are being sold by Evolus.

Evolus is a performance beauty company focused on delivering breakthrough products in the self-pay aesthetic market. Co.'s product, Jeuveau™ (prabotulinumtoxinA-xvfs), is a 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Co.'s primary market is the self-pay aesthetic market, which includes medical products purchased by physicians that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance.

EOLS SEC Filing Email Alerts Service

Open the EOLS Page at The Online Investor »

Company Name: 
Evolus Inc
Drugs & Pharmaceuticals
Number of ETFs Holding EOLS: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the EOLS Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Buy (3.33 out of 4)
50th percentile
(ranked higher than approx. 50% of all stocks covered)

Analysts' Target Price:
EOLS Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.